Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
OS Therapies Stock
OS Therapies Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul A. Romness
- Employees
- 5
- Market cap
- $62 M
- IPO
- 01/08/2024
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable…
OS Therapies stock: price history
1D
-6.4%
1W
-18.5%
1M
-24.6%
6M
-5.0%
YTD
-5.7%
1Y
-28.6%
2Y
-58.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~62% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about OS Therapies
Analyst assessment of OS Therapies
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 19/05/2026
OS Therapies stock metrics
P/E
-1.21
P/B
-5.34
EV/EBITDA
-1.7
RETURN ON EQUITY
79.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.0%
FLOAT SHARES
25,970,036
AVG. DAILY VOLUME (30D)
834,729
Institutional holders
Comparable stocks
Frequently asked questions about OS Therapies stock
What does OS Therapies do?
OS Therapies Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul A. Romness, the company employs around 5 people.
The IPO was on 01/08/2024; the stock trades on AMEX under the ticker OSTX.
What do analysts say about OS Therapies stock?
4 analysts rate the stock, the consensus is Buy (as of 19/05/2026).
This is an external assessment, not a statement by Market Jury.
When does OS Therapies report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 62% stronger than usual.
Does OS Therapies pay a dividend?
No, OS Therapies currently does not pay a dividend.
Which stocks are comparable to OS Therapies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get OS Therapies stock analyzed?
Clicking "Analyze stock" lets five strategies assess OS Therapies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.